drugset
Drugs / allogeneic mesenchymal stem cell
last change Jan 2021 re-read 3 minutes ago

allogeneic mesenchymal stem cell

Cell therapy

Developed for
COVID-19
Investigated by
Daewoong Pharmaceutical Co. LTD. · Ina-Respond · National Institute of Health Research and Development, Ministry of Health Republic of Indonesia

Trials 1

today NCT04535856 · Ph 1
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04535856 Nov 2020 → Jan 2021 COVID-19 Ina-Respond Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as allogeneic mesenchymal stem cell ClinicalTrials.gov intervention name — accepted as the source's own label NCT04535856 ↗
Modality Cell therapy “Daewoong Pharmaceutical intends to develop cell therapy products using mesenchymal stem cells (MSC).” NCT04535856 ↗